Effects of IgLON5 Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration

Anti‐IgLON5 disease is a neurological disorder characterized by autoantibodies against IgLON5 and pathological evidence of neuronal‐specific tau accumulation. Here, we report that patients' IgLON5 IgG, but not other cell‐surface antibodies, disrupt the cytoskeletal organization in cultured rat hippocampal neurons, resulting in dystrophic neurites and axonal swelling. Adsorption of IgLON5 IgG with HEK293 cells expressing IgLON5 abrogated the indicated cytoskeletal changes. These findings, along with an increase of levels of neurofilaments in patients' cerebrospinal fluid, suggest that IgLON5 IgG, unlike other cell‐surface antibodies, disrupts neuronal cytoskeleton maintenance, providing a link between autoimmunity and neurodegeneration. ANN NEUROL 2020;88:1023–1027

[1]  D. Choi,et al.  Axonal degeneration in an in vitro model of ischemic white matter injury , 2019, Neurobiology of Disease.

[2]  E. Gelpí,et al.  Anti-IGLON5 disease , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[3]  X. Daura,et al.  HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[4]  K. Blennow,et al.  Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. , 2019, JAMA neurology.

[5]  J. Dalmau,et al.  Antibody-Mediated Encephalitis. , 2018, The New England journal of medicine.

[6]  Iryna Leshchyns’ka,et al.  Glycosylphosphatidylinositol-Anchored Immunoglobulin Superfamily Cell Adhesion Molecules and Their Role in Neuronal Development and Synapse Regulation , 2017, Front. Mol. Neurosci..

[7]  K. Josephs,et al.  IgLON5 antibody , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[8]  N. Brüggemann,et al.  Clinical manifestations of the anti-IgLON5 disease , 2017, Neurology.

[9]  J. Dalmau,et al.  Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome , 2016, Journal of Neuroinflammation.

[10]  W. Poewe,et al.  Neuropathological criteria of anti-IgLON5-related tauopathy , 2016, Acta Neuropathologica.

[11]  Alex Iranzo,et al.  A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study , 2014, The Lancet Neurology.

[12]  D. Booth,et al.  Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton , 2014, Neurology: Neuroimmunology & Neuroinflammation.

[13]  P. Insel,et al.  Interaction of membrane/lipid rafts with the cytoskeleton: impact on signaling and function: membrane/lipid rafts, mediators of cytoskeletal arrangement and cell signaling. , 2014, Biochimica et biophysica acta.

[14]  M. Won,et al.  Neuronal loss in primary long-term cortical culture involves neurodegeneration-like cell death via calpain and p35 processing, but not developmental apoptosis or aging , 2007, Experimental & Molecular Medicine.

[15]  E. Masliah,et al.  Axonopathy and Transport Deficits Early in the Pathogenesis of Alzheimer's Disease , 2005, Science.

[16]  M. Dichter,et al.  Electrophysiological comparison of pyramidal and stellate nonpyramidal neurons in dissociated cell culture of rat hippocampus , 1991, Brain Research Bulletin.